CDK8 and medullary thyroid gland carcinoma: MiR-592 promoted cellular proliferation in vitro and negatively regulated cyclin‐dependent kinase 8 (CDK8), suggesting that miR-592/CDK8 axis could be regarded as a potential target in treating MTC [51].